Centrexion Therapeutics

Executive Summary

Centrexion Therapeutics is a private, Boston-based biopharmaceutical company focused on developing non-opioid pain relief and immunology therapies. Founded in 2013, the company leverages a proven track record in drug development to address significant unmet medical needs. Its pipeline targets two emerging categories: non-opioid pain management and immunology, aiming to provide safer alternatives to current standards of care. While the company has not disclosed specific financials or pipeline details publicly, its experienced leadership and strategic portfolio construction position it as a potential player in these high-growth areas. The company's private status and limited public disclosures make it challenging to assess precisely, but its focus on areas with high clinical need suggests potential upside if clinical candidates advance successfully.

Upcoming Catalysts (preview)

• H2 2026Initiation or update of Phase 2 trial for lead non-opioid pain candidate40% success
• H1 2027Partnership or licensing deal for immunology asset30% success
• Q4 2026Series C financing round to support pipeline advancement50% success